Latanoprost ophthalmic Side Effects
Some side effects of latanoprost ophthalmic may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to latanoprost ophthalmic: ophthalmic solution
Get emergency medical help if you have any of these signs of an allergic reaction while taking latanoprost ophthalmic: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using latanoprost ophthalmic and call your doctor at once if you have any of these serious side effects:
redness, swelling, itching, or pain in or around your eye;
oozing or discharge from your eye;
increased sensitivity to light;
vision changes; or
Less serious side effects of latanoprost ophthalmic may include:
cold symptoms such as stuffy nose, sneezing, sore throat;
mild eye discomfort;
feeling like something is in your eye;
dry or watery eyes; or
stinging or burning of the eyes after using the drops.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to latanoprost ophthalmic: ophthalmic solution
Ocular side effects have been reported the most frequently. These have included blurred vision, burning and stinging, conjunctival hyperemia, foreign body sensation, itching, increased pigmentation of the iris, and punctate epithelial keratopathy in 5% to 15% of patients. Dry eye, excessive tearing, eye pain, lid crusting, lid discomfort/pain, lid edema, lid erythema and photophobia have been observed in 1% to 4% of patients. Conjunctivitis, diplopia and discharge from the eye have been reported in less than 1% of patients. Retinal artery embolus, retinal detachment, and vitreous hemorrhage from diabetic retinopathy have been reported rarely. Choroidal detachment, hypotony, macular edema (including cystoid macular edema), pigmented iris cysts, corneal edema, corneal erosions, keratitis, and herpes keratitis have also been reported. Paradoxical increases in intraocular pressure (IOP) and recurrence of uveal inflammation have been reported in patients with uveitic glaucoma. Periorbital and lid changes resulting in deepening of the eyelid sulcus have also been reported.
Latanoprost can increase the amount of brown pigment in the eye by stimulating melanin production in melanocytes. The change in eye color occurs gradually over months to years and may be permanent. The entire or parts of the iris may be affected. Changes may be more prominent in patients with green- brown, blue/gray- brown or yellow- brown irides.
Conjunctival hyperemia is generally most pronounced during the start of therapy and may subside following prolonged use. In clinical trials, the hyperemia tended to be mild or moderate and rarely resulted in withdrawal from therapy.
A 6- month multicenter, randomized, investigator- masked study (n=136) of patients receiving daily latanoprost therapy reported conjunctival hyperemia in up to 42.5% of patients and a single case of anterior uveitis requiring treatment with topical corticosteroids. The mean grade of hyperemia was 0.28 on a scale of 1 to 3.
An open-label, multinational, multicenter, uncontrolled study of latanoprost administered daily for up to 5 years reported an increase in iris pigmentation in one-third of patients. This effect was generally reported within the first 36 months of therapy in patients with nonhomogenous eye color. There appeared to be no effect on the efficacy or overall safety of latanoprost.
Respiratory side effects have included upper respiratory infections in 4% of patients. Asthma, exacerbation of asthma, and dyspnea have also been reported.
Musculoskeletal side effects have included arthralgias and myalgias (usually back pain) in 1% to 2% of patients.
Cardiovascular side effects have rarely included chest pain and angina pectoris (1% to 2%).
Hypersensitivity reactions have included rash or skin problems in 1% to 2% of patients.
The manufacturer reports eyelash changes are usually reversible following discontinuation of therapy.
Four cases of poliosis have been reported in as early as 6 weeks of treatment. The affected lashes were interspersed with normally pigmented lashes. Hypertrichosis was also reported in 2 of the 4 patients.
A 6- month, multicenter, randomized, investigator- masked study (n=136) reported a single case of eyelash growth with daily latanoprost therapy.
A 61- year- old man reported his upper eyelashes had been obscuring his vision for approximately 2 months after instilling latanoprost daily to both eyes for approximately a 2- year duration. Further examination revealed bilateral trichomegaly with potentially irreversible lash ptosis.
Dermatologic side effects have rarely included reversible hyperpigmentation of the eyelids, eyelashes, periocular area, temporal area, neck, and back. Increase in length, thickness, and number of eyelashes and/or vellus hairs, changes in the direction of the growth of eyelashes, poliosis, contact dermatitis, and toxic epidermal necrolysis have also been reported. One case of lash ptosis has been reported.
Nervous system side effects have included postmarketing reports of dizziness and headache.
More latanoprost ophthalmic resources
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.